An Open, Uncontrolled Pilot Study on 12-Week Use of VagiVital for Treatment of Vulvovaginal Atrophy in Breast Cancer Patients Undergoing Adjuvant Aromatase-Inhibitor Therapy.

Med Devices (Auckl) · 2021 · PMC8242146 · PMID 34234580

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Highly significant improvements were also observed for the main secondary efficacy en points (vaginal pH, dryness, irritation/itching, dysuria, dyspareunia).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.